2014
DOI: 10.1021/bc5004313
|View full text |Cite
|
Sign up to set email alerts
|

Functionalizing Liposomes with anti-CD44 Aptamer for Selective Targeting of Cancer Cells

Abstract: CD44 receptor protein is found to be overexpressed by many tumors and is identified as one of the most common cancer stem cell surface markers including tumors affecting colon, breast, pancreas, and head and neck, making this an attractive receptor for therapeutic targeting. In this study, 2'-F-pyrimidine-containing RNA aptamer (Apt1), previously selected against CD44, was successfully conjugated to the surface of PEGylated liposomes using the thiol-maleimide click reaction. The conjugation of Apt1 to the surf… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
88
0
3

Year Published

2015
2015
2022
2022

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 159 publications
(96 citation statements)
references
References 34 publications
(52 reference statements)
2
88
0
3
Order By: Relevance
“…Although there is promising data emerging from the preclinical setting in the targeting of CD44, CD133, EpCAM, and CD90 (discussed below), the largest hurdle will be demonstrating safety and efficacy in vivo. Methodologies targeting CD44 include anti-CD44 monoclonal antibodies [106] and anti-CD44 antibody or aptamer-labelled liposomes [107,108]. The CD44 ligand, hyaluronic acid, has also been used to label nanocarriers and conjugates, with demonstrated efficacy in reducing CD44?…”
Section: Targeting Cancer Stem Cell Surface Markersmentioning
confidence: 99%
“…Although there is promising data emerging from the preclinical setting in the targeting of CD44, CD133, EpCAM, and CD90 (discussed below), the largest hurdle will be demonstrating safety and efficacy in vivo. Methodologies targeting CD44 include anti-CD44 monoclonal antibodies [106] and anti-CD44 antibody or aptamer-labelled liposomes [107,108]. The CD44 ligand, hyaluronic acid, has also been used to label nanocarriers and conjugates, with demonstrated efficacy in reducing CD44?…”
Section: Targeting Cancer Stem Cell Surface Markersmentioning
confidence: 99%
“…As we know, liposome is the most popular vector in current drug delivery due to its mature and simple preparation, high drug loadings, prolonged blood circulation half-lives, tumortargeting ability, and high in vivo biosafety. [35][36][37] Recently, several formulations of liposome-based DDSs have been approved by Food and Drug Administration and European Medicines Agency for the treatment of cancer. 38 Thus, in this study, DPPC, DSPE-PEG (common phospholipid material), and DOX (a water-soluble antitumor drug) were used to build a DOX-loaded liposome via film dispersion method.…”
Section: Discussionmentioning
confidence: 99%
“…Functionalization of DNA-Polymer (A) microcapsules; 34 and (B) Liposomes functionalized with CD44 Aptamer 35 .…”
Section: Figurementioning
confidence: 99%